1. Home
  2. HRTX vs TRVI Comparison

HRTX vs TRVI Comparison

Compare HRTX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRTX
  • TRVI
  • Stock Information
  • Founded
  • HRTX 1983
  • TRVI 2011
  • Country
  • HRTX United States
  • TRVI United States
  • Employees
  • HRTX 126
  • TRVI N/A
  • Industry
  • HRTX Biotechnology: Pharmaceutical Preparations
  • TRVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • HRTX Health Care
  • TRVI Health Care
  • Exchange
  • HRTX Nasdaq
  • TRVI Nasdaq
  • Market Cap
  • HRTX 240.3M
  • TRVI 211.4M
  • IPO Year
  • HRTX 1987
  • TRVI 2019
  • Fundamental
  • Price
  • HRTX $1.59
  • TRVI $4.05
  • Analyst Decision
  • HRTX Strong Buy
  • TRVI Strong Buy
  • Analyst Count
  • HRTX 3
  • TRVI 8
  • Target Price
  • HRTX $5.67
  • TRVI $9.31
  • AVG Volume (30 Days)
  • HRTX 6.2M
  • TRVI 4.2M
  • Earning Date
  • HRTX 11-12-2024
  • TRVI 11-06-2024
  • Dividend Yield
  • HRTX N/A
  • TRVI N/A
  • EPS Growth
  • HRTX N/A
  • TRVI N/A
  • EPS
  • HRTX N/A
  • TRVI N/A
  • Revenue
  • HRTX $137,737,000.00
  • TRVI N/A
  • Revenue This Year
  • HRTX $13.10
  • TRVI N/A
  • Revenue Next Year
  • HRTX $18.76
  • TRVI N/A
  • P/E Ratio
  • HRTX N/A
  • TRVI N/A
  • Revenue Growth
  • HRTX 12.13
  • TRVI N/A
  • 52 Week Low
  • HRTX $1.04
  • TRVI $1.27
  • 52 Week High
  • HRTX $3.93
  • TRVI $4.68
  • Technical
  • Relative Strength Index (RSI)
  • HRTX 50.28
  • TRVI 64.87
  • Support Level
  • HRTX $1.53
  • TRVI $4.08
  • Resistance Level
  • HRTX $1.88
  • TRVI $4.68
  • Average True Range (ATR)
  • HRTX 0.17
  • TRVI 0.38
  • MACD
  • HRTX 0.01
  • TRVI 0.15
  • Stochastic Oscillator
  • HRTX 47.67
  • TRVI 73.00

About HRTX Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: